Fundraising Fox

Bioluminescence Ventures

Venture capital

San Francisco

Fox Verdict
Sign up to see your fit

Fund manager profile

Bioluminescence Ventures is a venture fund manager based in San Francisco. SEC filings show 2 venture funds on record, most recently Bioluminescence Ventures Fund II, L.P. ($127.1M offering) filed September 2023.

Source: SEC EDGAR Form D filings. Firm website data not yet available.

HQ
San Francisco, US
Founded
2023
Tracked investments
5

What they invest in

from 3 of 5 portfolio companies

Biotech ×2Healthtech ×2Medical Devices ×2AI & Machine Learning ×1Cybersecurity ×1Data & Infrastructure ×1Enterprise Software ×1

HQs:United States×5

Investments · 5 tracked

founders shown can be your intro path

By year:2023 · 32022 · 12021 · 15 dated

Artificial, Inc.May 2021SEC filingmedium confidence

Palo Alto, US

Board seatKouki Harasaki· per SEC Form D · $22.2M raise · filed May 2021

Ensomaensoma.comMay 2023 · $50M

Ensoma is a genomic medicine company developing a platform for in vivo engineering of hematopoietic stem cells (HSCs), combining an off-the-shelf delivery system with a gene engineering toolkit intended to treat diseases with a one-time treatment.

BiotechHealthtechMedical DevicesBoston, US

Board seatKouki Harasaki· per SEC Form D

Co-investors5AM VenturesAju IB Invesment CorporationCatalio Capital Management, LPDelos CapitalF-Prime CapitalSolasta Ventures+7 more

Karlsgatekarlsgate.comin𝕏Mar 2022SEC filingmedium confidence

Karlsgate provides a data governance and identity protection platform (the Karlsgate Identity Exchange) that lets organizations match, share, and collaborate on sensitive data across partners and AI workflows without transmitting raw identifiers, using locally generated cryptonyms and single-use protected values.

CybersecurityData & InfrastructureEnterprise SoftwareBudd Lake, US

Brian Mulllin(Executive Officer, Director)Xian Zhou(Executive Officer, Director)Kouki Harasaki(Director)

Board seatKouki Harasaki· per SEC Form D · $5M raise · filed Mar 2022

Co-investorsMotley Fool Ventures

ReCode Therapeuticsrecodetx.comin𝕏Sep 2023SEC filingmedium confidence

ReCode develops mRNA and gene correction therapeutics for genetic diseases, using proprietary lipid nanoparticle technology to deliver treatments to specific organs.

AI & Machine LearningBiotechHealthtechMedical DevicesMenlo Park, US

Dr. Daniel J. SiegwartArthur E Johnson(Executive Officer, Director)

Board seatKouki Harasaki· per SEC Form D · $290M raise · filed Sep 2023

Co-investorsAju IB Invesment CorporationEcoR1 CapitalEvolution VC PartnersMPM BioImpactOrbiMedOUP (Osage University Partners)+6 more

SURGE Therapeutics, Inc.Jun 2023SEC filingmedium confidence

Cambridge, US

Board seatKouki Harasaki· per SEC Form D · $50M raise · filed Jun 2023

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.

Portfolio news

latest coverage across their companies

Frequently asked questions

Where is Bioluminescence Ventures located?
Bioluminescence Ventures is headquartered in San Francisco, US.

Featured in lists